A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis
RNA-seq (gene expression) · human · 100 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 100 samples: 45 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE266275_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1106492 and SRA study SRP505040. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 90 samples.
How we read this: 45 replicated groups read from 100 sample titles; they account for 90 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8244192 011V02D0 011V02D
- GSM8244193 011V02D1 011V02D
- GSM8244194 012V02D0 012V02D
- GSM8244195 012V02D1 012V02D
- GSM8244196 013V02D0 013V02D
- GSM8244197 013V02D1 013V02D
- GSM8244198 014V02D0 014V02D
- GSM8244199 014V02D1 014V02D
- GSM8244200 025V02D0 025V02D
- GSM8244201 025V02D1 025V02D
- GSM8244202 026V02D0 026V02D
- GSM8244203 026V02D1 026V02D
- GSM8244204 027V02D0 027V02D
- GSM8244205 027V02D1 027V02D
- GSM8244206 028V02D0 028V02D
- GSM8244207 028V02D1 028V02D
- GSM8244208 029V02D0 029V02D
- GSM8244209 029V02D1 029V02D
- GSM8244210 030V02D0 030V02D
- GSM8244211 030V02D1 030V02D
- GSM8244212 031V02D0 031V02D
- GSM8244213 031V02D1 031V02D
- GSM8244214 032V02D0 032V02D
- GSM8244215 032V02D1 032V02D
- GSM8244216 015V02D0 015V02D
- GSM8244217 015V02D1 015V02D
- GSM8244218 017V02D0 017V02D
- GSM8244219 017V02D1 017V02D
- GSM8244220 018V02D0 018V02D
- GSM8244221 018V02D1 018V02D
- GSM8244222 019V02D0 019V02D
- GSM8244223 019V02D1 019V02D
- GSM8244224 020V02D0 020V02D
- GSM8244225 020V02D1 020V02D
- GSM8244226 033V02D0 033V02D
- GSM8244227 033V02D1 033V02D
- GSM8244228 066V02D0
- GSM8244229 066V03D1
- GSM8244230 065V02D0
- GSM8244231 065V03D1
+ 60 more — browse all 100 samples with per-sample file links →
- GSE298762 NSAIDS-XDR-TB clinical trial: A randomized pilot study to estimate the potential efficacy and safety of using adjunctive ibuprofen for the treatment of pre-XDR and XDR tuberculosis 73 samples shares randomized, treatment, efficacy
- GSE327189 Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial 5 samples shares randomized, treatment, efficacy
- GSE252145 Transcriptomic Profile of Breast Tissue of Premenopausal Women Following Treatment with Progesterone Receptor Modulator: Secondary Outcomes of a Randomized Controlled Trial 32 samples shares randomized, treatment
- GSE179224 A phase 2 Randomized Controlled Trial of Adjuvant Tumor-Infiltrating Lymphocytes for Pretreatment Epstein-Barr Virus DNA-selected High-Risk Nasopharyngeal Carcinoma Patients 4 samples shares randomized, treatment
- GSE301131 Kimchi intake promotes antigen-presenting cell signaling and CD4⁺ T cell remodeling without inducing systemic immune activation: A single-cell RNA-seq substudy of a randomized, double-blind, placebo-controlled clinical trial 3 samples shares double-blind, randomized
- GSE212575 Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomized, phase 3 trial. 73 samples shares randomized, efficacy
- GSE240861 Ketogenicdiet versus standard high-carbohydrate nutrition in sepsis: a randomized controlled trial 100 samples shares randomized
- GSE271080 Randomized phase II trial of preoperative fulvestrant with or without enzalutamide for ER+/Her2- primary breast cancer 86 samples shares randomized
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.